Risk of second primary in situ and invasive melanoma in a Dutch population-based cohort: 1989-2008

British Journal of Dermatology

Volumn 167, Issue 6, 2012, Pages 1321-1330

  Van Der Leest, R J T ^a   Liu, L ^a   Coebergh, J W W ^a,b   Neumann, H A M ^a   Mooi, W J ^c   Nijsten, T ^a   De Vries, E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Cancer Registry   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; HUMAN; INVASIVE CUTANEOUS MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NETHERLANDS; RISK FACTORS; SKIN NEOPLASMS;

EID: 84870229945     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11123.x     Document Type: Article

References (37)

1. de Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-26.
2. Hollestein LM, van den Akker SA, Nijsten T, et al. Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2011; 23: 524-30.
3. Garbe C, Leiter U,. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3-9.
4. Hu S, Parmet Y, Allen G, et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch Dermatol 2009; 145: 1369-74.
5. Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-89.
6. Kasparian NA, McLoone JK, Butow PN,. Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 2009; 145: 1415-27.
7. de Giorgi V, Rossari S, Papi F, et al. Multiple primary melanoma: the impact of atypical naevi and follow up. Br J Dermatol 2010; 163: 1319-22.
8. Fields RC, Coit DG,. Evidence-based follow-up for the patient with melanoma. Surg Oncol Clin N Am 2011; 20: 181-200.
9. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
10. Balamurugan A, Rees JR, Kosary C, et al. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J Am Acad Dermatol 2011; 65: S69-77.
11. Karahalios E, English D, Thursfield V, et al. Second Primary Cancers in Victoria, Victorian Cancer Registry 1982-2005. 2009. Available at http://www.cancervic.org.au/about-our-research/epidemiology/second-primary- cancers-victoria (last accessed 2 July 2012).
12. Levi F, Randimbison L, Te VC, et al. High constant incidence rates of second cutaneous melanomas. Int J Cancer 2005; 117: 877-9.
13. Schmid-Wendtner MH, Baumert J, Wendtner CM, et al. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001; 145: 981-5.
14. Dong C, Hemminki K,. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. Int J Cancer 2001; 93: 155-61.
15. Wassberg C, Thorn M, Yuen J, et al. Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer 1999; 83: 314-17.
16. Burden AD, Vestey JP, Sirel JM, et al. Multiple primary melanoma: risk factors and prognostic implications. BMJ 1994; 309: 375.
17. Cantwell MM, Murray LJ, Catney D, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer 2009; 100: 174-7.
18. Soerjomataram I, Coebergh JW,. Epidemiology of multiple primary cancers. Methods Mol Biol 2009; 471: 85-105.
19. de Vries E, Karim-Kos HE, Janssen-Heijnen ML, et al. Explanations for worsening cancer survival. Nat Rev Clin Oncol 2010; 7: 60-3.
20. Schouten LJ, Straatman H, Kiemeney LA, et al. The capture-recapture method for estimation of cancer registry completeness: a useful tool? Int J Epidemiol 1994; 23: 1111-16.
21. Bradford PT, Freedman DM, Goldstein AM, et al. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010; 146: 265-72.
22. Duffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008; 168: 98-104.
23. Burden AD, Newell J, Andrew N, et al. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol 1999; 135: 261-5.
24. Siskind V, Hughes MC, Palmer JM, et al. Nevi, family history, and fair skin increase the risk of second primary melanoma. J Invest Dermatol 2011; 131: 461-7.
25. McCaul KA, Fritschi L, Baade P, et al. The incidence of second primary invasive melanoma in Queensland, 1982-2003. Cancer Causes Control 2008; 19: 451-8.
26. Glusac EJ,. The melanoma 'epidemic', a dermatopathologist's perspective. J Cutan Pathol 2011; 38: 264-7.
27. van der Rhee JI, Mooi WJ, Kukutsch NA, et al. Iatrogenic melanoma. Comment on: Melanoma epidemic: a midsummer night's dream? Br J Dermatol 2010; 162: 457-8.
28. Frangos JE, Duncan LM, Piris A, et al. Increased diagnosis of thin superficial spreading melanomas: a 20-year study. J Am Acad Dermatol 2011; 67: 387-94.
29. de Vries E, Coebergh JW,. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355-66.
30. Joosse A, de Vries E, Eckel R, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol 2011; 131: 719-26.
31. Francken AB, Bastiaannet E, Hoekstra HJ,. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6: 608-21.
32. Salerni G, Lovatto L, Carrera C, et al. Melanomas detected in a follow-up program compared with melanomas referred to a melanoma unit. Arch Dermatol 2011; 147: 549-55.
33. U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 188-93.
34. U.S. Preventive Services Task Force. Screening for skin cancer: recommendations and rationale. Am J Prev Med 2001; 20: 44-6.
35. Wolff T, Tai E, Miller T,. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 194-8.
36. Katris P, Donovan RJ, Gray BN,. Nurses screening for skin cancer: an observation study. Aust N Z J Public Health 1998; 22: 381-3.
37. Turner RM, Bell KJ, Morton RL, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 2011; 29: 4641-6.